• Home
  • American Society of Clinical Oncology Annual Meeting 2026

ASCO 2026


Chicago, IL

American Society of Clinical Oncology Annual Meeting 2026
Explore more Oncology congress materials
Material Type

Results(12)

Oncology
Beamion BCGC-1: Four New Phase Ib/II Cohorts to Evaluate Oral Zongertinib With Other Agents in HER2-Positive Metastatic Breast Cancer (mBC) and Metastatic Colorectal Cancer (mCRC)
Author(s): Kohei Shitara, Izuma Nakayama, Shigehisa Kitano et al.
Combining Zanidatamab, FOLFOX, and Pembrolizumab as First-Line Therapy for HER2/PD-L1–Positive Gastroesophageal Adenocarcinoma – the phase ll IKF/AIO ZANGEA trial with translational analysis
Author(s): Joseph Tintelnot, Eray Gökkurt, Salah-Eddin Al-Batran et al.
Trial in Progress: A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab for advanced soft tissue sarcomas (NCT05876715)​
Author(s): Samantha Jeffrey, Sant P. Chawla, Oliver Davidorf et al.
Comparison of Real-World Overall Survival Between Atezolizumab- and Durvalumab-Containing First‐Line Induction and Maintenance Regimens in Extensive-Stage Small Cell Lung Cancer
Author(s): Apar Kishor Ganti, Jeremy Snider, Jessie T Yan et al.
Safety and Pharmacokinetics of Lurbinectedin in Pediatric Patients With Relapsed/Refractory Solid Tumors and Preliminary Antitumor Activity in Pediatric and Young Adult Patients With Relapsed/Refractory Ewing Sarcoma: Results From a Phase 1 Study
Author(s): Julia Lynne Glade Bender, Joseph Gerald Pressey, Lars M Wagner et al.
Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the ​ Phase 3 IMforte study of lurbinectedin + atezolizumab maintenance treatment in extensive-stage ​ small-cell lung cancer
Author(s): Luis G. Paz-Ares, Hossein Borghaei, Martin Reck et al.
Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402
Author(s): Firas Benyamine Badin, Philip E Lammers, Geoffrey Liu et al.
IMforte: Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of FirstLine Maintenance Treatment With Lurbinectedin + Atezolizumab vs Atezolizumab in Extensive-Stage Small Cell Lung Cancer
Author(s): Hossein Borghaei, Luis Paz-Ares, Martin Reck et al.
Real-World Treatment Patterns and Overall Survival in Patients With HER2-Positive Advanced or Metastatic Gastroesophageal Adenocarcinomas in the US
Author(s): Farshid Dayyani, Xiaozhou Fan, Joan Zape et al.